Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr. Reddy's Laboratories Ltd. closed 12.96% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories sees a weekly return of 3.53%
Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...
Dr Reddy's in pact with Shanghai Henlius Biotech for exclusive US, Europe rights for daratumumab biosimilar
HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...
Pharmabiz19h
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
money.rediff19h
Dr Reddy's Subsidiary Partners with Henlius for Cancer Drug
Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and ...
Hosted on MSN2d
Dr. Reddy’s Laboratories Engages with Investors in Upcoming Conferences
An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...
devdiscourse19h
Dr Reddy's and Shanghai Henlius Join Forces for Cancer Breakthrough
Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...
Dr Reddy's unit ties up with Shanghai Henlius Biotech
Dr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the ...
Dr. Reddy's Laboratories outperforms market on strong trading day
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.68% to 1,227.95 Indian rupees Wednesday, on what proved to be an ...
Dr Reddy’s arm ties up with Shanghai Henlius Biotech
Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius Biotech, Inc to develop and commercialise an under-development cancer drug. Dr Reddy’s ...